Overall, HCQ may reduce disease activity and preeclampsia risk in SLE pregnancies but appears to be ineffective in patients with isolated aPL positivity or APS, and it does not significantly reduce the risk of intrauterine growth restriction [35]. The gene discussed is FASLG; the disease is fetal growth restriction.